Congress Wealth Management LLC DE Purchases 952 Shares of DexCom, Inc. (NASDAQ:DXCM)

Congress Wealth Management LLC DE increased its position in DexCom, Inc. (NASDAQ:DXCM) by 0.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 168,657 shares of the medical device company’s stock after buying an additional 952 shares during the period. Congress Wealth Management LLC DE’s holdings in DexCom were worth $23,393,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. DSM Capital Partners LLC bought a new position in shares of DexCom in the 4th quarter valued at about $28,000. Valley National Advisers Inc. lifted its stake in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. Riverview Trust Co acquired a new stake in shares of DexCom during the first quarter worth $32,000. MV Capital Management Inc. lifted its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the period. Finally, Smithfield Trust Co lifted its stake in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DXCM. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Raymond James lifted their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Redburn Atlantic initiated coverage on shares of DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price for the company. Canaccord Genuity Group boosted their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Trading Down 1.1 %

Shares of NASDAQ:DXCM traded down $1.21 during mid-day trading on Monday, reaching $112.17. 2,583,600 shares of the company were exchanged, compared to its average volume of 2,957,132. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The firm has a market cap of $44.61 billion, a price-to-earnings ratio of 72.37, a P/E/G ratio of 2.77 and a beta of 1.16. The firm’s 50-day simple moving average is $122.75 and its 200 day simple moving average is $125.65. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. Equities research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Activity

In related news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,735 shares of company stock worth $7,619,347. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.